RSS Feeds

Press releases

Press releases

Displaying 1..10 of 11 - per page Next page
Order by
Two papers on Embil's novel triple-active topical products (Neo-Penotran® Forte and Neo-Penotran® Forte-L) have been accepted for presentation at the 4'th World Conference on Vaginitis, Costa Rica, 10-13 Jan 2004 More
Two new Clinical Study reports of Neo-Penotran® Forte are to be presented at the 10'th International Congress on Infectious Diseases meeting to be held in Singapore between 11-14 March 2002. More
New summary from Partneringdesk highlights trends in dealmaking from the top pharma and biotech companies More
Alliance Pharma plc, (LSE.APH) the Chippenham-based emerging speciality pharmaceutical company, today announced that it has commenced the registration trial programme for its development drug APL202 (misoprostol) for the induction of labour. More
STOWIC's IP and processes have been acquired by United Pharmaceuticals of Jordan. More
Intendis GmbH and Foamix Ltd have executed a worldwide license agreement for a dermatological foam More
Foamix is partnering with leading phamaceutical companies in developing their drugs in foam formulations. The company will present at the upcoming American Academy of Dermatology meeting in New Orleans on February 18-22, 2005 More
Ness Ziona ISRAEL, April 7, 2005 - Foamix Ltd., a leader in developing innovative topical delivery systems, enters new state-of-the-art facility. More
Warner Chilcott Company, Inc. and Foamix Ltd. announced today that the two companies have signed an agreement to jointly develop an antibiotic foam for the treatment of acne. More
Foamix Ltd. announced today that on November 22, 2005 the United States Patent and Trademark Office (USPTO) issued to Foamix Patent No. 6,967,023. More
Displaying 1..10 of 11 - per page Next page
Order by

Related Reports

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2014 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us